about
Neuromodulation of chronic headaches: position statement from the European Headache Federation.Improving care through health economics analyses: cost of illness and headacheGenetics of migraine and pharmacogenomics: some considerationsIctal epileptic headache: an old story with courses and appealsAspirin and tension-type headacheFuture drugs for migraineProinflammatory mediators and migraine pathogenesis: moving towards CGRP as a target for a novel therapeutic classPsychiatric comorbidity and suicide risk in patients with chronic migraineOnabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centersImproving quality in population surveys of headache prevalence, burden and cost: key methodological considerations.Anti-CGRP monoclonal antibodies in migraine: current perspectives.Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation.CGRP receptor antagonists: an expanding drug class for acute migraine?Inflammatory mechanisms in cervicogenic headache: an integrative view.A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraineQuestioning on consistency of a stagnation scale in medication overuse headache: one more added to a plea of emperor's clothes?Chronic migraine plus medication overuse headache: two entities or not?Psychometric properties of the stagnation scale in medication overuse headache patients.Cervicogenic headache: practical approaches to therapy.Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative studyPatient outcome in migraine prophylaxis: the role of psychopharmacological agentsSalivary cortisol, dehydroepiandrosterone-sulphate (DHEA-S) and testosterone in women with chronic migraine.Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk.The validation of the Italian Perceived Disability Scale (IPDS) in chronic daily headache sufferers.The Global Campaign (GC) to Reduce the Burden of Headache Worldwide. The International Team for Specialist Education (ITSE)Cytotoxic T lymphocyte antigen 4 polymorphism 49 (A>G) and migraineHeadache and mood disorders.Mental turmoil, suicide risk, illness perception, and temperament, and their impact on quality of life in chronic daily headache.Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience.Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine.Migraine with aura, bipolar depression, ACM aneurysm. A case report.White matter hyperintensities and self-reported depression in a sample of patients with chronic headacheOnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study.O065. Drug-resistant chronic cluster headache successfully treated with supraorbital plus occipital nerve stimulation. A rare case reportA two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.Prevalence and burden of primary headache in Akaki textile mill workers, EthiopiaP064. 12 years of Master Degree in Headache Medicine at Sapienza University of Rome.Altered serum levels of kynurenine metabolites in patients affected by cluster headacheImpact of migraine on fibromyalgia symptoms.New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters?
P50
Q21146948-6D0A8F48-7098-4C67-B35F-4436CF490D7CQ24595978-5D2B3C83-D1FE-49E2-98AF-D9A67439F357Q24654656-C98D209C-7A01-4FDF-8BD9-BC337DBFF232Q27001097-2A5E6EFE-47A0-4246-808B-A7DE4EFB9A5DQ28213497-61FD41C6-6721-462F-B201-1890F3D45964Q28249721-15DFF000-061B-4892-9AF9-CD1247A2BF87Q28292548-61269C7F-543C-4EE9-AF32-324E81F6012AQ33787213-B96D6C41-5A2A-4CA9-A8EE-5186672A75F8Q33860731-61C5D172-DF30-43D5-9FF7-E56D55F83137Q34507965-D4258393-BAF6-4DFA-9718-C65658C47175Q34531880-6A1262FE-4444-4EBE-A8A3-3BBC73D8C318Q34544375-8E522BE3-8A73-459C-BFD2-F7B3E00FCFEDQ34637610-77AAA9B0-BFAA-48F2-8835-D9DA21CFCD06Q34719441-C97503EC-150E-4BA8-8E70-4638A2787881Q34981791-6EA260F9-3EA0-41A0-9EBD-444FA606AFE3Q35264506-2688618F-B421-4EDC-8B79-ABA987A21510Q35522746-7D6F5762-C1CD-4FC7-AF3C-42ECC6EA3B2EQ35599467-D0096A34-ED83-483C-A00F-2C77D1217F82Q35891548-89229CC1-36FB-4AD0-8D6F-C446594F5200Q36052155-75327F06-1B35-473D-9437-E5AB59D734A0Q36160565-1C0F0012-4B64-4D9E-87F9-97AD174BF570Q36259651-57A12A0B-5523-45D4-901D-D52C532216A8Q36259780-9C5AEA10-8746-440E-B54B-17C4BE8DD58BQ36259835-8E2BB8F3-E27D-4B31-9ABC-155FC0C55BD0Q36260419-6F15E1A3-FAC2-4425-9F7E-2F7341F1A7CEQ36260478-004A9774-D021-4D56-9654-80C54FD6BE8AQ36260487-6657D4FC-263D-419F-AEE9-C9B318CED490Q36260621-7578ED53-0E9E-4C11-AD61-7EE8B79C2DD5Q36261002-620F610A-C0DB-4C05-AC18-7FB5815B91AEQ36261201-E80BE3E5-EB79-4EB0-91C9-3E06142B00E2Q36261326-2DCC2394-4553-4C25-9C13-11C57BEDCA98Q36357119-C1899B26-7A79-44A1-894B-30CAE146C229Q36415380-2C8A25ED-5754-4946-8487-5388C144F089Q36468422-85ADB6B0-B91C-4B8F-9E33-A00EF578B2F0Q36484239-B4363A77-BE9E-4BC6-B252-D9DA7EFB24C2Q36511877-1CE7623D-E81A-42BD-A0D8-3946D5931703Q36594928-7F2CA43A-CBA1-4F76-86FF-DB52C94F02EDQ36712255-712B71B8-769C-45BC-921A-559DBC629927Q36717622-CF6C9467-315A-4AAB-9B04-2491DE846A4FQ36750079-B73CE778-FE04-4290-AC60-DE1F4F8BC34E
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paolo Martelletti
@ast
Paolo Martelletti
@en
Paolo Martelletti
@es
Paolo Martelletti
@nl
Paolo Martelletti
@sl
type
label
Paolo Martelletti
@ast
Paolo Martelletti
@en
Paolo Martelletti
@es
Paolo Martelletti
@nl
Paolo Martelletti
@sl
prefLabel
Paolo Martelletti
@ast
Paolo Martelletti
@en
Paolo Martelletti
@es
Paolo Martelletti
@nl
Paolo Martelletti
@sl
P106
P21
P31
P496
0000-0002-6556-4128